About us

We bring more than hope

We are Pancreatic Cancer UK. We go above and beyond for everyone affected by this disease. Right now, half of people with pancreatic cancer die within three months of diagnosis. Families are left with only hope to hold onto. They need more. So, we do more.

We bring more breakthroughs through research, more change through campaigning, and more support through our expert nurses. We make more noise because people have gone unheard. We are relentless because the disease is ruthless. We care more because people feel forgotten.

Because people with pancreatic cancer need more than hope.

Campaigners

Our vision and mission

We won’t stop until we achieve our vision – for everyone with pancreatic cancer to live long and well. Read our five-year strategy. 

Read more
runner with two PCUK workers

Our people

Our people make all of this possible – an incredible community of staff, volunteers and supporters. Amazing people, just like you.

Read more

Our vacancies

We’re committed to supporting people with pancreatic cancer right now, and funding research and campaigning to transform the future.  

Read more
lewis

What we do

We bring more change through campaigning, more breakthroughs through research and more support through expert nurses.

Find out what we do
  • Just 12% of pancreatic cancer patients given the chance to join a clinical trial

    Just 12% of pancreatic cancer patients given the chance to join a clinical trial

    Only 12% of people with pancreatic cancer are given the chance to take part in a clinical trial, emphasising the lack of progress in developing treatm...

  • We’re demanding treatment breakthroughs. We’re demanding survival.

    We’re demanding treatment breakthroughs. We’re demanding survival.

    Today marks the launch of our Demand Survival Now petition, calling on governments across the UK to fund more research for treatment breakthroughs

  • Our response to the daraxonrasib clinical study and KRAS inhibitors

    Our response to the daraxonrasib clinical study and KRAS inhibitors

    Our comment on daraxonrasib results and the promising group of therapies known as KRAS inhibitors.